Skip to content

Effect of anti-TNF-a therapy on cognition in patients with Crohn's disease

Effect of anti-TNF-a therapy on cognition in patients with Crohn's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061270
Enrollment
Unknown
Registered
2022-06-18
Start date
2022-06-06
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

None listed

Sponsors

The Second Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the WHO diagnostic criteria for Crohn's disease; 2. Identify CD patients on anti-TNF-a therapy (infliximab or adalimumab).

Exclusion criteria

Exclusion criteria: 1. Crohn's disease patients who are not newly diagnosed and treated for the first time; 2. People with mental retardation, hearing or visual impairment who cannot complete the questionnaire; 3. Those who use psychoactive drugs (including anxiolytics, antipsychotics, antidepressants and opioid-based pain relievers); 4. People with a history of alcoholism.

Design outcomes

Primary

MeasureTime frame
Cognitive scale;Tumor necrosis factor-alpha, TNF-a;Interleukin-6;Procalcitonin, PCT;

Secondary

MeasureTime frame
Inflammatory Bowel Disease Quality of Life Questionnaire;

Countries

China

Contacts

Public ContactXiangpeng Hu

The Second Affiliated Hospital of Anhui Medical University

Xphuay2003@aliyun.com+86 18756039192

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026